Clinical Trial Update: Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating golidocitinib vs placebo as maintenance therapy for Peripheral T-cell lymphoma patients who achieved a response after first-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Golidocitinib (golidocitinib)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Peripheral T Cell Lymphoma | Phase 3 | Status: RECRUITING